Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.45 |
| ▸ | NOTCH1 | P46531 | 2/20 | 0.44 |
| ▸ | RBPJ | Q06330 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP7 | P09237 | 2/20 | 0.42 |
| ▸ | MMP10 | P09238 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559068 | 0.91 | APP (0.41) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4557718 | 0.91 | APP (0.41) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4559113 | 0.90 | APP (0.40) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4559378 | 0.90 | APP (0.63) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4559317 | 0.88 | APP (0.57) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13934580 | 0.86 | APP (0.65) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13920941 | 0.86 | APP (0.65) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4559364 | 0.81 | APP (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4559866 | 0.81 | APP (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4557783 | 0.80 | APP (0.51) | APPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102752-B1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-10-19 | — | — | EP | claimed |
| US-6794381-B1 | BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-21 | — | — | US | claimed |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-07-17 | — | — | US | claimed |
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7304055-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7153491-B2 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060258638-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-11-16 | — | — | US | disclosed |
| US-7101870-B2 | Succinoylamino lactams as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-6962913-B2 | Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1589342-A2 | Use of radioligands to screen inhibitors of amyloid-beta peptide production | Bristol-Myers Squibb Pharma Company (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1102752-B1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1129355-B1 | USE OF RADIOLIGANDS TO SCREEN INHIBITORS OF AMYLOID-BETA PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6878363-B2 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050019255-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | ZACZEK ROBERT (US) | 2005-01-27 | — | — | US | disclosed |
| US-6794381-B1 | BETA -PEPTIDE INHIBITOR PREVENTS NEUROLOGICAL DEPOSITS OF AMYLOID PRECURSOR PROTEIN; ALZHEIMER'S DISEASE AND DOWN'S SYNDROME TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-21 | — | — | US | disclosed |
| US-6737038-B1 | CONTACTING POTENTIAL INHIBITOR AND TAGGED INHIBITOR OF BETA-AMYLOID PRODUCTION WITH MACROMOLECULE CONTAINING BINDING SITE SPECIFIC FOR TAGGED INHIBITOR, SEPARATING BOUND INHIBITOR, DETERMINING INHIBITORY CONCENTRATION | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-18 | — | — | US | disclosed |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-07-17 | — | — | US | disclosed |
| US-20020159947-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6331408-B1 | CONTACTING A POTENTIAL INHIBITOR OF BETA-AMYLOID PRODUCTION AND TAGGED INHIBITOR OF BETA-AMYLOID PRODUCTION WITH AT MACROMOLECULE INVOLVED IN PROCESSING OF AMYLOID PRECURSOR PROTEIN; SEPARATING TAGGED INHIBITOR, DETERMINING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020159947-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | APP, BACE1, BACE2 | APP 1/4885PSEN1 5/4885PSEN2 6/4885 |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BACE1, APH1A, APP | APP 3/4885PSEN1 7/4885PSEN2 9/4885 |
| US-20060258638-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | BACE1, APH1A, APP | APP 3/4885PSEN1 7/4885PSEN2 9/4885 |
| US-20050019255-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | APP, BACE1, BACE2 | APP 1/4885PSEN1 4/4885PSEN2 6/4885 |
| US-20030134841-A1 | Succinoylamino lactams as inhibitors of A-beta protein production | APH1A, BACE1, APP | APP 3/4885PSEN1 7/4885PSEN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.